DIABETES, TYPE II, SUSCEPTIBILITY TO
|
phenotype |
|
Finding
|
1
|
2
|
0.100 |
None |
|
0 |
2
|
|
|
New Onset Diabetes After Transplant
|
disease |
Nutritional and Metabolic Diseases; Endocrine System Diseases
|
Disease or Syndrome
|
6
|
1
|
0.010 |
None |
1.000 |
1 |
|
2015 |
2015 |
Hypomenorrhea
|
phenotype |
Pathological Conditions, Signs and Symptoms
|
Disease or Syndrome
|
20
|
2
|
0.010 |
None |
1.000 |
1 |
|
2019 |
2019 |
progesterone receptor-positive breast cancer
|
disease |
|
Neoplastic Process
|
28
|
17
|
0.010 |
None |
1.000 |
1 |
|
2003 |
2003 |
Decreased waist to hip ratio
|
phenotype |
|
Finding
|
28
|
|
0.100 |
None |
|
0 |
|
|
|
Atrophy of testis
|
disease |
Male Urogenital Diseases; Endocrine System Diseases
|
Disease or Syndrome
|
29
|
|
0.010 |
None |
1.000 |
1 |
|
2019 |
2019 |
Hyperglycemia, Postprandial
|
phenotype |
Nutritional and Metabolic Diseases
|
Finding
|
37
|
|
0.300 |
None |
1.000 |
2 |
|
2010 |
2015 |
Medullomyoblastoma
|
disease |
Neoplasms
|
Neoplastic Process
|
43
|
|
0.300 |
None |
1.000 |
1 |
|
2009 |
2009 |
Melanotic medulloblastoma
|
disease |
Neoplasms
|
Neoplastic Process
|
43
|
|
0.300 |
None |
1.000 |
1 |
|
2009 |
2009 |
Desmoplastic Medulloblastoma
|
disease |
Neoplasms
|
Neoplastic Process
|
54
|
1
|
0.300 |
None |
1.000 |
1 |
|
2009 |
2009 |
Resistance to Insulin-Like Growth Factor I
|
disease |
Pathological Conditions, Signs and Symptoms; Congenital, Hereditary, and Neonatal Diseases and Abnormalities
|
Disease or Syndrome
|
55
|
4
|
0.020 |
None |
1.000 |
2 |
|
2008 |
2010 |
Anovulatory (finding)
|
disease |
Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases
|
Disease or Syndrome
|
55
|
8
|
0.010 |
None |
1.000 |
1 |
|
2019 |
2019 |
Insulin Sensitivity
|
phenotype |
Nutritional and Metabolic Diseases
|
Pathologic Function
|
62
|
|
0.300 |
None |
1.000 |
1 |
|
2015 |
2015 |
FATTY LIVER DISEASE, NONALCOHOLIC, SUSCEPTIBILITY TO, 1
|
disease |
|
Finding
|
63
|
2
|
0.200 |
None |
1.000 |
1 |
|
2011 |
2011 |
LIVER DISEASE, ALCOHOLIC, SUSCEPTIBILITY TO, 1
|
phenotype |
|
Finding
|
63
|
|
0.200 |
None |
1.000 |
1 |
|
2011 |
2011 |
FATTY LIVER DISEASE, NONALCOHOLIC, SUSCEPTIBILITY TO, 2
|
phenotype |
|
Finding
|
63
|
|
0.200 |
None |
1.000 |
1 |
|
2011 |
2011 |
Chemical Carcinogenesis
|
phenotype |
Pathological Conditions, Signs and Symptoms; Neoplasms
|
Neoplastic Process
|
71
|
2
|
0.010 |
None |
1.000 |
1 |
|
2017 |
2017 |
Adenoviral infections
|
group |
|
Disease or Syndrome
|
78
|
1
|
0.010 |
None |
1.000 |
1 |
|
2009 |
2009 |
Overweight and obesity
|
disease |
|
Disease or Syndrome
|
81
|
29
|
0.010 |
None |
1.000 |
1 |
|
2016 |
2016 |
Invasive Lobular Breast Carcinoma
|
disease |
Neoplasms; Skin and Connective Tissue Diseases
|
Neoplastic Process
|
88
|
|
0.010 |
None |
1.000 |
1 |
|
2018 |
2018 |
Postoperative cognitive dysfunction
|
phenotype |
|
Mental or Behavioral Dysfunction
|
93
|
|
0.010 |
None |
1.000 |
1 |
|
2019 |
2019 |
Hyperandrogenism
|
disease |
Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Endocrine System Diseases
|
Disease or Syndrome
|
108
|
24
|
0.010 |
None |
1.000 |
1 |
|
2004 |
2004 |
Alloxan Diabetes
|
disease |
Nutritional and Metabolic Diseases; Endocrine System Diseases
|
Experimental Model of Disease
|
112
|
|
0.300 |
None |
1.000 |
1 |
|
2015 |
2015 |
Streptozotocin Diabetes
|
disease |
Nutritional and Metabolic Diseases; Endocrine System Diseases
|
Experimental Model of Disease
|
112
|
|
0.300 |
None |
1.000 |
1 |
|
2015 |
2015 |
Hyperplasia
|
phenotype |
Pathological Conditions, Signs and Symptoms
|
Pathologic Function
|
131
|
|
0.020 |
None |
1.000 |
2 |
|
2004 |
2006 |